Floatz logo

Ropidoxuridine

Cancer

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
81/ 100

Competitive context

1411 Active assets in the Cancer cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Vitamin B6
M.D. Anderson Cancer Center
Phase 4BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB
Rivoceranib
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BB
PROPOFOL
Hong Kong Children's Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Ropidoxuridine is also rated in:

IDH-wildtype glioblastomaDormant
CC
Indicative ·
47 / 100
View asset →
bile duct carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →